Skip to main content
INAB
NASDAQ Life Sciences

IN8BIO Launches $2.8M At-The-Market Offering to Address Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.82
Mkt Cap
$18.414M
52W Low
$1.17
52W High
$5.61
52W Position info
56% above low
Off High info
68% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

INAB sits 56% above its 52-week low of $1.17.

Summary

IN8BIO has launched an At-The-Market offering to sell up to $2.8 million in common stock, a crucial step to secure funding given its 'going concern' warning and limited cash runway.


Key Events · Financing and Capital Events · INAB

  • At-The-Market Offering Launched

    IN8BIO has entered into a Sales Agreement to offer and sell up to $2.8 million of common stock through an At-The-Market (ATM) program.

  • Significant Potential Dilution

    The offering represents approximately 15.2% of the company's current market capitalization and could issue around 1.5 million new shares, leading to substantial dilution for existing shareholders.

  • Addresses Going Concern Warning

    This capital raise is a direct response to the company's previously disclosed 'going concern' warning and a cash runway projected only through April 2027, making it vital for continued operations.

  • Follows Prior Shelf Registration

    This 424B5 prospectus supplement finalizes the terms of a capital raise under the S-3/A shelf registration filed on May 18, 2026, which allowed for up to $200 million in various securities.


Analysis · INAB · Life Sciences

IN8BIO has initiated an At-The-Market (ATM) offering to sell up to $2.8 million in common stock. This capital raise is critical for the company, which recently disclosed a 'going concern' warning and a cash runway extending only through April 2027. While dilutive for existing shareholders, this offering provides much-needed capital to extend operations and fund clinical development, directly addressing the company's immediate financial distress. This filing finalizes the terms of a capital raise previously indicated by the S-3/A shelf registration filed on May 18, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INAB was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $1.17 to $5.61. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INAB - Latest Insights

INAB
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.820
Real-time Price: $0.802 info
Change: -$0.018 (-2%) info
Market Cap: $8.863M info
INAB
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.840
Real-time Price: $0.802 info
Change: -$0.038 (-5%) info
Market Cap: $8.863M info
INAB
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.9888
Real-time Price: $0.802 info
Change: -$0.1868 (-19%) info
Market Cap: $8.863M info
INAB
Jul 09, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.802 info
Change: -$0.588 (-42%) info
Market Cap: $8.863M info
INAB
Jun 01, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.93
Real-time Price: $0.802 info
Change: -$1.13 (-58%) info
Market Cap: $8.863M info